Roche, Trimeris Select HIV Drug Candidates

Roche and Trimeris, Inc. have selected two next-generation fusion inhibitor peptides for co-development and progression into further preclinical studies as part of an ongoing collaboration in the development and commercialization of fusion inhibitors for the treatment of HIV/AIDS. The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment from Roche.

TR-291144 and TR-290999 are being developed with the goal of achieving durable suppression of HIV by increasing the potency of the molecules and raising their genetic barrier to the development of resistance. Also central to the development program is increased patient convenience via simpler, more patient-friendly administration, with a target of once-weekly dosing.

“The future of these new fusion inhibitor peptide candidates is quite promising,” said Nick Cammack, Ph.D., vice president and head of Viral Diseases Research, Roche. “This development is reflective of our continued commitment to developing new strategies to help manage patients with HIV.”

“We are very encouraged by the prospect of co-developing the next generation of fusion inhibitor peptides with our colleagues at Roche,” said Steven D. Skolsky, chief executive officer, Trimeris, Inc. “This is a significant milestone which further validates our peptide technology platform.”